Achieve Life Sciences, Inc. Q4 2025 Earnings Call Summary

Strategic Transformation and Operational Context - Achieve Life Sciences has transitioned from a clinical development firm to a commercially focused enterprise following the June 2025 NDA submission for cytisinicline [5] - The ORCA-OL study demonstrated safety and tolerability over 52 weeks, addressing long-term treatment concerns and attributed strong clinical momentum [5] - A significant market opportunity has been identified among the 6 million COPD smokers in the U.S., with post-hoc data showing cytisinicline significantly improved quit rates [5] Launch Strategy and Regulatory Outlook - The company has pivoted to a lean, omnichannel commercial model, recognizing that 75% of primary care physicians no longer meet with traditional medical representatives [5] - Anticipated commercial launch is set for the first half of 2027, allowing time for manufacturing scale-up and establishing a robust U.S. supply chain [5] - The company is leveraging the Commissioner's National Priority Voucher to expedite the vaping cessation indication, targeting a review timeline of 1 to 2 months [5] Supply Chain and Risk Factors - Strategic selection of Adare Pharma Solutions for U.S. manufacturing aims to secure the supply chain and mitigate risks from international tariffs and importation uncertainties [5] - The company maintains a strategic stockpile of raw starting material sufficient for more than 3 years of market demand to ensure long-term supply continuity [5] - Two FDA GMP inspection observations at the current NDA-named manufacturer have prompted an accelerated technology transfer to Adare Pharma Solutions [5] Q&A Session Highlights - There is a noted gap between the June approval and the H1 2027 launch timing, with a focus on ensuring supply reliability through U.S.-based manufacturing [6][7] - The geopolitical rationale for onshoring manufacturing to the U.S. is highlighted to provide redundancy and contingency capacity [7]